KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to -$2.2 million.

  • Biomarin Pharmaceutical's Cash from Financing Activities rose 99.57% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.7 million, marking a year-over-year increase of 91.77%. This contributed to the annual value of -$526.4 million for FY2024, which is 2711.17% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Cash from Financing Activities of -$2.2 million as of Q3 2025, which was up 52.88% from -$4.6 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Cash from Financing Activities high stood at $14.4 million for Q4 2021, and its period low was -$499.1 million during Q3 2024.
  • Its 3-year average for Cash from Financing Activities is -$53.7 million, with a median of -$2.2 million in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 831.43% in 2022, then slumped by 63,240.74% in 2024.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Cash from Financing Activities stood at $14.4 million in 2021, then dropped by 24.50% to $10.9 million in 2022, then decreased by 0.27% to $10.8 million in 2023, then tumbled by 73.63% to $2.9 million in 2024, then soared by 99.57% to -$2.2 million in 2025.
  • Its Cash from Financing Activities was -$2.2 million in Q3 2025, compared to -$4.6 million in Q2 2025 and -$38.8 million in Q1 2025.